Work

Low Omicron BA.4 and BA.5 neutralising activity and breakthrough COVID-19 following pre-exposure prophylaxis with tixagevimab plus cilgavimab in vaccinated patients with autoimmune disease

Year: 2022

Type: article

Source: Clinical and Experimental Rheumatology

DOI: 10.55563/clinexprheumatol/pfli7o

Authors: Caoilfhionn M. Connolly, Andrew H. Karaba, Teresa Po-Yu Chiang, Mayan Teles, Jake D. Kim, Trevor Scott Johnson, Jennifer L. Alejo, Dorry L. Segev, Lisa Christopher-Stine, William A. Werbel, Julie J. Paik

Institutions: Johns Hopkins University, Johns Hopkins Medicine, Johns Hopkins Hospital, New York University

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Health and Human Services, Pfizer, AstraZeneca, Sanofi, Alexion Pharmaceuticals, CSL Behring, Regeneron Pharmaceuticals, Jazz Pharmaceuticals, Novavax, Jerome L. Greene Foundation, CareDx, Argenx, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Awards: Patient Oriented Research in Solid Organ Transplantation, Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer Risk, Clinical and Laboratory Research Training for Gastrointestinal Surgeons, Modulation of Herpes Simplex Virus Pathogenesis by Leucine Rich Repeat Kinase 2, The Landscape of Serious Infections following Kidney Transplantation in People Living with HIV, Skeletal Myopathy in Systemic Sclerosis: Devising a Classification Schema Predictive of Outcomes

OpenAlex ID: W4321749025

FWCI: 0.61

Cites: 5

Cited by: 5

Related to: 10